Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Sees Significant Decline in Short Interest

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) saw a large drop in short interest in November. As of November 30th, there was short interest totalling 1,590,000 shares, a drop of 69.5% from the November 15th total of 5,220,000 shares. Approximately 0.9% of the shares of the stock are short sold. Based on an average daily trading volume, of 34,310,000 shares, the short-interest ratio is presently 0.0 days.

Tonix Pharmaceuticals Trading Up 5.1 %

Tonix Pharmaceuticals stock traded up $0.01 during mid-day trading on Friday, hitting $0.24. The company’s stock had a trading volume of 45,440,418 shares, compared to its average volume of 15,009,065. The business has a 50 day moving average price of $0.17 and a 200-day moving average price of $0.66. Tonix Pharmaceuticals has a 12 month low of $0.12 and a 12 month high of $22.14. The stock has a market cap of $44.95 million, a price-to-earnings ratio of 0.00 and a beta of 2.23. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.03) by $1.80. The company had revenue of $2.82 million during the quarter, compared to analyst estimates of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. As a group, analysts forecast that Tonix Pharmaceuticals will post -17.63 EPS for the current year.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on Tonix Pharmaceuticals in a research note on Saturday, December 7th. They issued a “sell” rating for the company.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.